| Theme | New Drugs for Dialysis Patients | |
|---|---|---|
| Title | Novel therapeutic agents in renal osteodystrophy management | |
| Publish Date | 2006/06 | |
| Author | Takeshi Hasegawa | Division of Nephrology, Department of Internal Medicine, Showa University Fajigaoka Hospital |
| Author | Fumihiko Koiwa | Division of Nephrology, Department of Internal Medicine, Showa University Fajigaoka Hospital |
| [ Summary ] | Recently, the management of renal osteodystrophy has been targeted not only to correct bone metabolism abnormalities but also to attenuate vascular calcification which lower patient outcome. High serum calcium x phosphate products aggravate vascular calcification, therefore we have hoped for the development of novel phosphate binders and hyperparathyroidism drugs, which would not produce calcium overload. For that reason, we have been using sevelamer hydrochloride since 2003. Calcimimetics that inhibit parathyroid hormone (PTH) secretion and reduce serum calcium concentrations will also be available in the near future. We may use many treatments for renal osteodystrophy and should choose suitable therapies with a complete understanding of each therapeutic agent. | |